CSS
ELVN icon

Cubist Systematic Strategies’s Enliven Therapeutics ELVN Stock Holding History

Cubist Systematic Strategies’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8,986
Closed -$197K – 3713
2023
Q1 		$197K Buy
8,986
+5,786
+181% +$118K ﹤0.01% 3241
2022
Q4 		$52.4K Buy
+3,200
New +$51.1K ﹤0.01% 3897
2021
Q4 		– Sell
-2,996
Closed -$49K – 3503
2021
Q3 		$49K Buy
+2,996
New +$62.2K ﹤0.01% 2837

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cubist Systematic Strategies's ELVN Position: Q2 2023 in Review

Cubist Systematic Strategies sold out of Enliven Therapeutics (ELVN) in Q2 2023, closing a stake of 8,986 shares — an estimated $197K sold.

Cubist Systematic Strategies first reported a position in ELVN in Q3 2021 and held it in 3 quarters. The position peaked at $197K in Q1 2023. 63 funds tracked by Wall St. Rank hold ELVN as of Q2 2023.

  • Cubist Systematic Strategies reported no remaining Enliven Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Cubist Systematic Strategies sold 8,986 Enliven Therapeutics shares in Q2 2023, an estimated $197K.
  • Cubist Systematic Strategies first reported a position in Enliven Therapeutics in Q3 2021 and held it in 3 quarters.
  • Cubist Systematic Strategies's Enliven Therapeutics position peaked at $197K in Q1 2023.
  • 63 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2023.

Based on Cubist Systematic Strategies's 13F filing for Q2 2023, filed 14 Aug 2023.